| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CA125 |
| Entrez GeneID | 94025 |
| clone | 1E1B9 |
| WB Predicted band size | 1519kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human MUC16 (AA: extra 1-200) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于MUC16抗体的参考文献摘要(注：文献信息为模拟示例，实际引用需核实来源)：
1. **"A novel monoclonal antibody targeting MUC16 for ovarian cancer diagnostics"**
- 作者：Smith A, et al.
- 摘要：开发了一种新型抗MUC16单克隆抗体，通过免疫组化验证其在卵巢癌组织中的高特异性结合，显示其作为液体活检和影像诊断工具的潜力。
2. **"Engineered anti-MUC16 CAR-T cells exhibit potent antitumor activity in pancreatic cancer models"**
- 作者：Chen L, et al.
- 摘要：研究构建了靶向MUC16的CAR-T细胞，在胰腺癌小鼠模型中显著抑制肿瘤生长，并探讨了其通过激活T细胞免疫应答的作用机制。
3. **"MUC16 antibody-drug conjugate for targeted therapy of chemoresistant cancers"**
- 作者：Wang Y, et al.
- 摘要：报道了一种MUC16抗体-药物偶联物(ADC)，在化疗耐药的卵巢癌和乳腺癌细胞系中显示出选择性杀伤效果，提示其临床转化前景。
建议通过PubMed或Web of Science检索真实文献，使用关键词“MUC16 antibody”、“anti-MUC16 therapeutic”等获取具体研究。
**Background of MUC16 Antibodies**
MUC16. also known as CA125. is a high-molecular-weight glycoprotein belonging to the mucin family. It is characterized by tandem repeat domains, a transmembrane region, and a cytoplasmic tail. Overexpressed in epithelial cancers, particularly ovarian cancer, MUC16 plays roles in cell adhesion, metastasis, and immune evasion, making it a key tumor biomarker and therapeutic target.
MUC16 antibodies are primarily developed to detect or target this glycoprotein for diagnostic and therapeutic purposes. In diagnostics, anti-MUC16 antibodies form the basis of CA125 immunoassays, widely used for monitoring ovarian cancer progression and recurrence. Therapeutically, MUC16-directed antibodies, such as monoclonal antibodies (mAbs), are explored for antibody-drug conjugates (ADCs) or immune checkpoint blockade. For instance, DMUC5754A (an ADC) targets MUC16-positive tumors, while CAR-T therapies utilize MUC16-binding domains for tumor-specific cytotoxicity.
Challenges in MUC16 antibody development include its structural complexity, extensive glycosylation, and heterogeneity across tumors. Antibodies often target immunodominant regions like the tandem repeat or SEA (sea-urchin sperm protein, enterokinase, and agrin) domains, but epitope variability can affect specificity. Additionally, soluble MUC16 shed into circulation may interfere with antibody efficacy.
Research continues to optimize MUC16 antibodies for improved sensitivity in diagnostics and enhanced tumor targeting in therapies, reflecting their critical role in cancer management.
×
